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Background: Studies on the influence of congenital heart disease (CHD) on neonates
with necrotizing enterocolitis (NEC) have produced varied results. We therefore examined
the influence of CHD on NEC outcomes.
Methods: We carried out a retrospective single-center study including infants with
confirmed NEC, treated between 2004 and 2017. We excluded patients with isolated
patent ductus arteriosus or pulmonary hypertension (n = 45) and compared outcomes
of patients with hemodynamically relevant CHD (n= 38) and those without CHD (n= 91).
Results: Patients with CHD were more mature than those without CHD [gestational
age, median, 95% confidence interval (CI95), 37.1, 34.5–37.2w, vs. 32.6, 31.9–33.3w;
P < 0.01]. The presence of CHD did not influence the frequencies of severe disease
(overall 21% Bell stage III), nor surgical interventions (overall 30%), the occurrence of
intestinal complications (overall 13%), nor the duration of hospitalization (overall 38 days
in survivors). The overall mortality as well as NEC-related mortality was increased with
the presence of CHD, being 50% (19 out of 38) and 13% (5 out of 38), respectively,
when compared to patients without CHD, being 8% (7 out of 91) and 3% (3 out of 91).
The presence of CHD and of advanced NEC stage III were independent predictors of
NEC-associated fatalities with multivariable odds ratios (CI95) of 7.0, 1.3–39.5 for CHD,
and of 3.4, 1.6–7.5 for stage III disease.
Conclusions: While some outcome parameters in neonates with NEC remained
unaffected by the presence of CHD, the mortality risk for patients with CHD was seven
times higher than without CHD.
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INTRODUCTION
The presence of congenital heart disease (CHD) has an unclear impact on overall morbidity and
mortality in neonates suffering from necrotizing enterocolitis (NEC), with prior studies having
conflicting results. A study carried out by Pickard et al. showed the somewhat surprising result (1)
that patients with NECwho also suffered fromCHDhad a significant survival advantage.While this
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was a relatively large study, there was a notable heterogeneity
among the patient groups and its transferability is an area of
concern. In addition, these results could not be supported by
other publications claiming a worse outcome of NEC in the
presence of CHD (2, 3).
We suspect that in the study carried out by Pickard et al.
a disproportionate number of NEC severities between the
study groups (NEC without CHD vs. NEC with CHD) might
have influenced the study outcome, thus resulting in better
outcomes for patients with both NEC and CHD. The latter group
comprised of more patients with suspected NEC (29 vs. 21%) and
less patients with advanced NEC (22 vs. 44%) (1).
Meanwhile, other studies argued that infants with both NEC
and CHD had worse outcomes than patients who had only one
of the two diseases (2, 3). In the study by Ostlie et al. the number
of infants with NEC and CHD was very small (n = 6), Fisher
et al. on the other hand, only included patients with a birth weight
below 1,500 g. In addition, it is not apparent from these studies if
patients died due to NEC or due to other causes. Finally, except
in the study from Pickard et al. there are currently no other
studies addressing intestinal complications such as ileus or short
gut syndrome.
Our aim was to gain more insight into the influence of
CHD on patients suffering from NEC. We therefore compared
outcomes between NEC patients with and without CHD, only
including confirmed cases of NEC and assessing intestinal
complications.
MATERIALS AND METHODS
We performed a retrospective review of the institutional
database of the Bern University Hospital and identified
infants who suffered from NEC between December 2004
and May 2017. The local ethics committee approved our
study project. We first excluded patients with isolated patent
ductus arteriosus (PDA), pulmonary hypertension, spontaneous
intestinal perforation, and suspected NEC (Bell stage I) (4).
We previously published the outcome data from a cohort
of infants who had NEC and PDA (5). We performed Bell
staging based on patient chart review, including radiographies
by two out of four independent senior physicians (UK, MN,
PK, SB) (4), and resolved disagreement by discussion in all
cases. Based on the most recent echocardiography report before
the diagnosis of NEC, we subdivided CHDs into different
categories.
We defined the following target variables: overall mortality,
mortality due to NEC, disease severity (Bell stage), surgical
intervention for NEC, duration of hospital stay, occurrence of
a relevant intestinal complication like the recurrence of NEC,
stricture or stenosis, intestinal failure, defined as prolonged
parenteral nutrition (>40 days), short gut syndrome, or—
if relevant—others. In addition, we extracted the following
data: gestational age (GA, weeks, w), birth weight (BW,
grams, g), gender, Apgar scores, age at disease onset (d), and
routine laboratory parameters at disease onset and at maximum
deviation from the normal value during the acute phase of NEC.
Death was assumed to be the consequence of NEC when the
treating physicians primarily attributed death to acute worsening
of NEC, and not to cardiac disease.
We used SPSS version 21 (IBM, SPSS, Chicago, IL, USA) for
the statistical analysis. We tested data for normality and equal
distribution via analysis of skewness and kurtosis and performed
the Kolmogorov-Smirnov test. We also made comparisons
between groups using student’s t-test, non-parametric tests or
analysis of variance (ANOVA) (as required, respectively) for
continuous variables as well as Chi-square or Fisher’s exact test
(as required, respectively) for categorical variables.
To assess the influence of CHD and disease severity, we carried
out univariable and multivariable logistic regression analysis for
each outcome parameter. We adjusted multivariable regression
for BW, gestational age, and postnatal age at onset of NEC. Data
is given as median and 95% confidence interval of the mean
(CI95) for continuous variables, and as percentage and frequency
for categorical variables unless otherwise specified. We used
two-sided tests throughout. P < 0.05 was considered significant.
RESULTS
Of 174 patients included in this study with confirmed NEC,
45 infants had isolated PDA or pulmonary hypertension and
therefore had to be excluded. Ninety-one infants with NEC had
no CHD and 38 infants with NEC had a relevant CHD (see
Figure 1, Table 1). Gestational age and BW were significantly
higher in the patients with CHD (median, CI95:37.1, 34.5–37.2w;
2,483, 2086–2634 g) than in those without CHD (32.6, 31.9–
33.3w; 1,700, 1633–1938 g; P < 0.01, respectively) (see Table 2).
While all laboratory parameters significantly changed during
the acute phase of the disease in both patient groups, we
nevertheless found some relevant differences between them:
hemoglobin concentrations were lower at baseline and during
disease in subjects with CHD as compared to those without CHD
(P < 0.05, respectively) (see Table 3). In addition, patients with
CHD had higher baseline levels of CRP as well as higher excess
levels of CRP (see Table 3).
There was a trend toward increased disease severity (Bell
stage 211 III) in NEC with CHD (29%) as compared to NEC
without 212 CHD (18%; overall 21%). The frequency of surgical
intervention 213 (overall 30%), the duration of hospitalization
(38 d in survivors) 214 and occurrence of intestinal complications
(overall 13%) were comparable in the two groups (see Table 4).
Overall mortality was lower in patients who had no CHD (7
out of 91, 8%) as compared to the subjects that had CHD (19 out
of 42, 50%; P < 0.01). NEC-associated mortality was also lower
in the patients without CHD (3 out of 91, 3%) as compared to
the patients with CHD (5 out of 42, 13%; P < 0.05), resulting
in an elevated odds ratio for NEC-attributable fatality if CHD
was present (univariable OR 7.4, 95% confidence interval 1.6–
33.5; P < 0.01; multivariable OR 7.0, 95% CI 1.3–39.6; P <
0.05, respectively). The second independent risk factor for NEC-
attributable fatality was high severity of disease (Bell stage III)
(univariable OR 3.2, 95% CI 1.6–6.4; P < 0.01; multivariable
OR 3.4, 95% CI 1.6–7.5; P < 0.01). Comparing the individual
Frontiers in Pediatrics | www.frontiersin.org 2 October 2018 | Volume 6 | Article 312
Kessler et al. CHD Increases NEC–Mortality
FIGURE 1 | Flow chart of selection of patient with NEC with or without CHD. NEC, necrotizing enterocolitis. CHD, congenital heart disease. PDA, patent ductus
arteriosus.
TABLE 1 | Types and frequencies of CHDs in the group of 38 infants with
complex CHD and NEC.
CHD–type n Additional defects
ASD 3
Aortic stenosis 2




Coarctation of aorta 3 1 AVSD
Double outlet right ventricle 1 1 VSD, ASD, AS, AR




Interrupted aortic arch 1 1 ASD, VSD
PDA 4 2 ASD, 1 PHT, 1 VSD
Tetralogy of Fallot 2 1 AVSD
Total anomalous pulmonary
venous return
2 1 TGA, AVSD; 1 ASD
Transposition of the great
arteries
3 1 PDA, ASD; 1 AVSD
Tricuspid atresia 2 1 VSD; 1 pulmonary atresia, ASD
Truncus arteriosus 3 1 insufficiency of truncal valve, 1 ASD
VSD 3 1 ASD, 1 PDA, 1 PFO
AR, aortic regurgitation; AS, aortic stenosis; ASD, atrial septal defect; AVSD,
atrioventricular septal defect; PDA, patent ductus arteriosus; PFO, persistent foramen
ovale; PHT, pulmonary hypertension; TGA, transposition of the great arteries; VSD,
ventricular septal defect.
subgroups of CHD patients in terms of outcomes, no differences
could be identified (data not shown).
DISCUSSION
The main result of the present investigation is that patients with
confirmed NEC had higher rates of overall and of NEC-related
mortality if they additionally suffered from CHD. Our results of
worse outcome in NEC patients with CHD compared to patients






Male gender, n (%) 46 (51%) 22 (58%)
Gestational age (w), median,
CI95
32.6 (31.9–33.3) 37.1 (34.5–37.2)*




Apgar 1’, median, CI95 6.0, 5.4–6.3 6.0, 4.8–6.6
Apgar 5’, median, CI95 8.0, 7.4–8.1 8.0, 6.6–8.2
Apgar 10’, median, CI95 9.0, 8.3–8.9 8.0, 7.4–8.7
Age at diagnosis of NEC (d),
median, CI95
6.0, 8.2–12.0 7.5, 10.1–23.6
*P < 0.01.
without CHD are not contradictory to the above-cited results
of Pickard et al. Firstly, while Pickard et al. included infants
with suspected NEC (at an unbalanced ratio of 29% in infants
with CHD vs. 21% in infants without CHD), we only assessed
outcomes in patients with confirmed NEC (1). Secondly, while
Pickard et al. had a lower number of grade III NEC infants in
CHD patients (22%) than in patients without CHD (44%), we
could show a comparable rate of severe diseases (Bell stage III)
in both groups (1).
The poor outcome for NEC patients with concomitant CHD
has already been described in a number of studies, but these
also included patients with Bell stage I and lacked a comparison
with the data provided by NEC patients without CHD (6, 7).
Furthermore, these studies only included pre-term infants (8) or
patients who were treated surgically (9).
A significantly higher mortality in NEC patients with CHD
has been shown in a prospective study by Fisher et al. with
a stringent NEC definition and a very specific comparison.
However, this study only concerned VLBW infants with a
gestational age of 30 weeks or younger (3). Increased mortality
in children with CHD (and also with late onset of NEC), has been
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TABLE 3 | Routine laboratory parameters at disease onset and their maximum abnormality during disease.






















152, 148–161 123, 121–132 136, 126–146 110, 101–116 P < 0.05 P < 0.01
Platelet count (G/l), median,
CI95
251, 242–301 186, 172–225 189, 177–273 107, 106–197 NS NS
WBC count (G/l), median,
CI95
9.0, 10.0–14.3 14.9, 17.0–21.9 9.0, 8.4–13.0 17.9, 16.2–22.9 NS P < 0.05
CRP (mg/dl), median, CI95 5, 9–22 33, 44–73 27, 27–67 102, 80–148 NS P < 0.05
Lactate concentration
(mg/dl), median, CI95
2.1, 2.1–3.0 2.3, 2.6–3.6 2.3, 2.4–5.0 3.4, 3.3–7.5 NS P < 0.05
Base excess (mmol/l),
median, CI95
−1.3, −0.8 to −2.5 −2.7, −2.3 to−4.1 −3.8, −1.9 to−5.1 5.5, −4.5 to 10.0 NS P < 0.01
Laboratory changes within groups between onset and maximum abnormality was significant at a P <0.05 for all laboratory parameters in both groups, respectively. NS, not significant;
WBC count, white blood cell count; CRP, C-reactive protein.










Severe disease, Bell stage III, n (%) 16 (18%) 11 (29%)
Surgery for NEC, n (%) 26 (29%) 13 (34%)
Overall mortality, n (%) 7 (8%) 19 (50%)*
NEC- related mortality, n (%) 3 (3%) 5 (13%)* 7.4, 1.6–33.5; P < 0.05 7.0, 1.3–39.6; P < 0.05
Intestinal complications in survivors, n (%) 11 (13%) 2 (11%)
Duration of hospital stay in survivors, median, CI95 38d, 39–60 d 50d, 41–69 d – –
CI95, 95% confidence interval; ICU, intensive care unit; OR, odds ration *P < 0.05.
shown by Short et al. However, this study only included full-term
infants (10).
A further study suggested that the outcome of NEC in pre-
term and full-term infants might be similar, using a cohort
of 277 patients with various gestational age. This relatively
large population however only included 26 full-term patients
and only six of them suffered from CHD. Consequently, no
specific comparison between patients with NEC and CHD and
NEC without CHD was possible and no significant difference
in mortality could be shown (2). Hence, the present study is,
to the best of our knowledge, the first investigation comparing
patients with established NEC (Bell stage≥ II) without CHD and
NEC patients with CHD, including both pre-term and full-term
patients.
We were able to show that some laboratory parameters
differed significantly in children with CHD and those without.
Children with a concomitant CHD had a lower white blood
cell (WBC) count and higher C-reactive protein (CRP) values
as well as lower base excess. The exact significance of this
difference remains unclear.While animal studies have shown that
polymorphonuclear neutrophils play an important role in the
pathogenesis of NEC (11), it is still not clear if local (intestinal)
pathology can be demonstrated by blood analyzes. Previous
attempts to find a correlation between higher CRP orWBC count
and disease severity in NEC have been hampered (12), but there is
a scale to assess the severity of NEC, which uses WBC count and
base excess as predictors, thus treating neutropenia and low base
excess as additional risk factors (13). It has also been shown that
lower WBC count correlates with poor outcome (14). CRP, on
the other hand, is used as a marker of imminent complications
(15). Overall, the difference in WBC count and CRP as well as
base excess could reflect the disease severity in CHD patients.
However, further research is needed to clarify this.
The hemoglobin values were also lower in children with CHD.
It has been shown that anemia is a risk factor for the development
of NEC (16). Children with lower hematocrit also tend to have
a higher risk for transfusion-associated NEC (17). Hence, the
lower concentration could contribute to disease severity. That
said, children with CHD were also older and could have lower
hemoglobin concentrations due to their gestational age.
A third result of our study is that although mortality is
increased in patients with CHD, surviving patients do not
have more intestinal complications than patients without CHD
do. This is an important finding, in line with the findings
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of Pickard et al. because, as we could recently show in a
meta-analysis, gastrointestinal sequelae are a frequent problem,
which should not be underestimated when assessing disease
outcome (18).
Strengths
This is, to the best of our knowledge, the second study to
compare intestinal outcomes in NEC patients with and without
CHD. Including pre-term as well as full-term patients and a
BW over 1,500 g, this study also draws on the biggest patient
cohort. Furthermore, the fact that we only included patients with
confirmed NEC is certainly a great strength of this study. In this
way, we could reduce the potential bias of deviation toward better
outcomes in patient groups with suspected NEC. Finally, we
performed a thorough review of patient charts, including many
variables including ones that allowed us to assess NEC-related
mortality and intestinal complications.
Shortcomings and Limitations
Our study certainly has some limitations. The retrospective study
design engenders several potential sources for bias. In addition,
the long inclusion period of more than 12 years bears a multitude
of possible confounders influencing the results, for example, the
changing intensive care protocols, different feeding habits or
new surgical approaches. However, we are convinced that the
duration of inclusion has a relatively small influence on the
assessed outcome parameters because the year of birth was not
correlated with mortality rate in our cohort. A comparatively
stable mortality rate of 360 NEC patients in the period from 1986
to 1999, as reported by Luig and Lui (19), supports our result of a
stable mortality rate over time (19).
It can be suggested that some subgroups of CHD even cause
worse NEC outcomes as compared to others, but there is still no
proof for this assumption (3). Since we only examined a relatively
small number of CHD patients, we were unable to confirm or
refute this hypothesis.
Unfortunately, it was not possible for us to determine if
patients with CHD were treated more aggressively than those
without CHD. However, since all included patients received
clinical and radiological workup as well as withdrawal of enteral
feeds and intravenous antibiotic treatment at disease onset, it is
very likely that initial patient management has little impact on
the outcome.
Finally, there is also some risk of bias in our definition of
mortality. In the absence of objective criteria, we assumed that
patients died due to NEC whenever the treating physicians
claimed so. However, it is likely that the health condition of
patients with co-morbidities might have deteriorated due to
cardiac causes or others and not due to enterocolitis itself.
Unfortunately, it was not possible to evaluate this retrospectively.
Nevertheless, the diagnostic criterion stated by the physicians is
widely used, also in studies particularly evaluating the mortality
(20). Finally, while most of the existing studies are rather non-
specific, our study is one of the few that also defines the cause of
death (2, 3).
CONCLUSION
We conclude that patients with established NEC and CHD
are more mature and have a seven-fold increased mortality
risk in comparison to NEC patients without CHD. Our results
also suggest that CHD-associated NEC could be seen as a
separate entity, with a different pathogenesis than classical NEC.
Furthermore, we believe that special care must be taken and
aggressive treatment must be considered in the management of
NEC patients with a concomitant CHD because of its much
poorer outcome.
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